An updated approach to the diagnosis of myeloid leukemia cutis

American Journal of Clinical Pathology

Volumn 132, Issue 1, 2009, Pages 101-110

  Cronin, Danielle M P ^a   George, Tracy I ^a   Sundram, Uma N ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Blastic plasmacytoid dendritic cell neoplasm; CD34; CD4+ CD56+ hematodermic neoplasm; Flow cytometry; Immunohistochemistry; Myeloid leukemia cutis; Myeloid sarcoma; World Health Organization classification

Indexed keywords

CD163 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; LEUKOSIALIN; MYELOPEROXIDASE; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MYELOID LEUKEMIA; MYELOID LEUKEMIA CUTIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; BONE MARROW CELLS; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PEROXIDASE; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 67650502791     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP6GR8BDEXPKHR     Document Type: Article

References (41)

1. Weedon D. Cutaneous infiltrates of other leukemias/lymphomas. In: Skin Pathology. 2nd ed. New York, NY: Churchill Livingstone; 2002:1118-1119.
2. Byrd JC, Edenfield WJ, Shields DJ, et al. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol. 1995;13:1800-1816.
3. Agis H, Weltermann A, Fonatsch C, et al. A comparative study on demographic, hematologic, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol. 2002;81:90-95.
4. Baer MR, Barcos M, Farrell H, et al. Acute myelogenous leukemia with leukemia cutis: eighteen cases seen between 1969 and 1986. Cancer. 1989;63:2192-2200.
5. Seymour JF, Pierce SA, Kantarjian HM, et al. Investigation of karyotypic, morphologic, and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 1994;8:823-826.
6. Su WP, Buechner SA, Li CY. Clinicopathologic correlations in leukemia cutis. J Am Acad Dermatol. 1984;11:121-128.
7. Buechner SA, Li CY, Su WP. Leukemia cutis: a histopathologic study of 42 cases. Am J Dermatopathol. 1985;7:109-119.
8. Roth MJ, Medeiros LJ, Elenitoba-Johnson K, et al. Extramedullary myeloid cell tumors: an immunohistochemical study of 29 cases using routinely fixed and processed paraffin-embedded tissue sections. Arch Pathol Lab Med. 1995;119:790-798.
9. Ratnam KV, Ziesmer SC, Li CY, et al. Value of immunohistochemistry in the diagnosis of leukemia cutis: study of 54 cases using paraffin-section markers. J Cutan Pathol. 1992;19:193-200.
10. Kaddu S, Zenahlik P, Beham-Schmid C, et al. Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria. J Am Acad Dermatol. 1999;40:966-978.
11. Sepp N, Radaszkiewicz T, Meijer CJ, et al. Specific skin manifestations in acute leukemia with monocytic differentiation: a morphologic and immunohistochemical study of 11 cases. Cancer. 1993;71:124-132.
12. Davey FR, Olson S, Kurec AS, et al. The immunophenotyping of extramedullary myeloid cell tumors in paraffin-embedded tissue sections. Am J Surg Pathol. 1988;12:699-707.
13. Cibull TL, Thomas AB, O'Malley DP, et al. Myeloid leukemia cutis: a histologic and immunohistochemical review. J Cutan Pathol. 2008;35:180-185.
14. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
15. WHO Classification of Tumours; vol 2.
16. Sundram U, Harvell JD, Rouse RV, et al. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol. 2003;16:802-810.
17. Sen F, Zhang XX, Prieto VG, et al. Increased incidence of trisomy 8 in acute myeloid leukemia with skin infiltration (leukemia cutis). Diagn Mol Pathol. 2000;9:190-194.
18. Ferrara F, Cancemi D, Friso P, et al. Tetrasomy 8 and t(1;11)(p32;q24) in acute myelo-monocytic leukemia with extensive leukemic cutaneous involvement. Leuk Lymphoma. 1996;20:513-515.
19. Macedo A, San Miguel JF, Vidriales MB, et al. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol. 1996;49:15-18.
20. Oelschlagel U, Nowak R, Schaub A, et al. Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia. Cytometry. 2000;42:247-253.
21. Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001;97:3574-3580.
22. Langebrake C, Brinkmann I, Teigler-Schlegel A, et al. Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring. Cytometry B Clin Cytom. 2005;63:1-9.
23. Dunphy CH, Polski JM, Evans HL, et al. Evaluation of bone marrow specimens with acute myelogenous leukemia for CD34, CD15, CD117, and myeloperoxidase. Arch Pathol Lab Med. 2001;125:1063-1069.
24. Dunphy CH, O'Malley DP, Perkins SL, et al. Analysis of immunohistochemical markers in bone marrow sections to evaluate for myelodysplastic syndromes and acute myeloid leukemias. Appl Immunohistochem Mol Morphol. 2007;15:154-159.
25. Arber DA, Jenkins KA. Paraffin section immunophenotyping of acute leukemias in bone marrow specimens. Am J Clin Pathol. 1996;106:462-468.
26. Hanson CA, Ross CW, Schnitzer B. Anti-CD34 immuno-peroxidase staining in paraffin sections of acute leukemia: comparison with flow cytometric immunophenotyping. Hum Pathol. 1992;23:26-32.
27. Kanter-Lewensohn L, Hellstrom-Lindberg E, Kock Y, et al. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry. Eur J Haematol. 1996;56:124-129.
28. Manaloor EJ, Neiman RS, Heilman DK, et al. Immuno-histochemistry can be used to subtype acute myeloid leukemia in routinely processed bone marrow biopsy specimens: comparison with flow cytometry. Am J Clin Pathol. 2000;113:814-822.
29. Nguyen TT, Schwartz EJ, West RB, et al. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol. 2005;29:617-624.
30. Sachdev R, Sundram U. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and factor XIIIa. J Cutan Pathol. 2006;33:353-360.
31. Cho-Vega JH, Medeiros LJ, Prieto VG, et al. Leukemia cutis. Am J Clin Pathol. 2008;129:130-142.
32. Sundram UN, Natkunam Y. Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis. J Cutan Pathol. 2007;34:289-295.
33. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123:662-675.
34. Pilichowska ME, Fleming MD, Pinkus JL, et al. CD4+/C56+ hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol. 2007;128:445-453.
35. Urosevic M, Conrad C, Kamarashev J, et al. CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. Hum Pathol. 2005;36:1020-1024.
36. Gopsca L, Banyai A, Jakab K, et al. Extensive flow cytometric characterization of plasmacytoid dendritic cell leukemia cells. Eur J Haematol. 2005;75:346-351.
37. Herling M, Teitell MA, Shen RR, et al. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+CD56+ blastic tumors of skin. Blood. 2003;101:5007-5009.
38. Ascani S, Massone C, Ferrara G, et al. CD4-negative variant of CD4+/CD56+ hematodermic neoplasm: description of three cases [published online ahead of print May 20, 2008]. J Cutan Pathol. 2008;35:911-915.
39. Assaf C, Gellrich S, Whittaker S, et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol. 2007;60:981-989.
40. Bekkenk MV, Jansen PM, Meijer CJ, et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004;15:1097-1108.
41. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501-4513.